Clinical Report: Ruxolitinib Treatment in Pediatric sJIA with MAS

Overview

This report reviews the efficacy and safety of ruxolitinib in two pediatric patients with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Both cases demonstrated clinical improvement, allowing for the tapering of glucocorticoids without relapse, as observed in the cases.

Background

Systemic juvenile idiopathic arthritis (sJIA) can lead to severe complications such as macrophage activation syndrome (MAS), which occurs in approximately 15-20% of patients, according to referenced studies. Effective management of refractory cases is critical, as traditional therapies may not suffice. Ruxolitinib, a JAK inhibitor, presents a potential therapeutic option for these challenging cases.

Data Highlights

Key Findings

• Both patients showed improvement in systemic hyperinflammation with ruxolitinib treatment, as observed.
• Glucocorticoids were tapered and discontinued in both cases without relapse, as reported.
• Case 1 experienced stabilization of body temperature and clinical symptom improvement after ruxolitinib initiation, as noted.
• Case 2 normalized body temperature within two days and ferritin levels within ten days of starting ruxolitinib, as observed.
• No ruxolitinib-related adverse events were reported in either case.
• Of seven previously reported pediatric cases, five achieved complete remission with ruxolitinib, as documented.

Clinical Implications

Clinicians should monitor for potential cytopenia and viral infections during treatment, as noted in the source material.

Conclusion

Further studies are warranted to establish the role of ruxolitinib in clinical practice, based on the findings from the reported cases.

Related Resources & Content

1. Frontiers in Pediatrics, 2026 -- Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review
2. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease - PMC
3. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis - PubMed
4. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) - PMC
5. Risk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis - PubMed
6. Bone Marrow Transplantation — Efficacy of Ruxolitinib in Managing Acute and Chronic Graft-Versus-Host Disease in Pediatric Patients: A Systematic Review and Meta-Analysis of Individual Patient Data
7. Frontiers in Immunology — Case Report: Treatment of refractory lung disease in systemic juvenile idiopathic arthritis with cyclophosphamide and rituximab combination therapy
8. Blood Cancer Journal — Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
9. The ASCO Post — Ruxolitinib Granted FDA Approval for Chronic Graft-vs-Host Disease
10. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease - PMC
11. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative - PubMed
12. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) - PMC
13. Risk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis - PubMed
14. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease - PMC
15. Efficacy and safety of emapalumab in macrophage activation syndrome - PubMed
16. Frontiers | Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review